MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$98,850K
Free Cash flow
-$100,132K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Proceeds from issuance of common...
Proceeds from maturities of avai...
Proceeds from issuance of common...
Others
Negative Cash Flow Breakdown
Purchases of available-for-sale ...
Net loss
Payments of common stock and pre...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2025-12-31
2025-09-30
2025-06-30
Net loss
-111,536
-49,787
-45,776
-78,762
Amortization of discount on available-for-sale securities
1,984
747
327
800
Equity-based compensation expense
10,768
6,500
3,928
6,486
Depreciation and amortization expense
786
467
376
793
Non-cash lease expense
1,257
611
598
1,162
Non-cash acquired in-process research and development
-
0
0
-
Common stock issued as upfront payment for collaboration and license agreement
-
0
-
-
Change in fair value of derivative liabilities
-2,500
-2,650
-850
-2,550
Other
-25
0
294
-55
Prepaid expenses and other assets
324
7,649
-1,716
2,060
Accounts payable
1,139
-5,257
3,697
467
Change in operating lease liability
-1,006
-495
-443
-848
Accrued expenses and other liabilities
-1,442
152
2,203
1,695
Net cash used in operating activities
-99,817
-53,555
-33,472
-69,262
Purchases of property and equipment
315
565
85
503
Proceeds from sale of property and equipment
-
85
-
-
Proceeds from maturities of available-for-sale securities
-146,880
-71,500
-38,000
-69,000
Purchases of available-for-sale securities
235,396
23,921
83,188
128,777
Other
85
-
0
-85
Net cash used in investing activities
-88,831
47,014
-45,273
-60,195
Proceeds from issuance of common stock and pre-funded warrants in public offering, net of underwriting discounts and commissions
0
0
0
189,637
Payments of common stock and pre-funded warrants issuance costs in public offering
0
0
0
1,681
Proceeds from issuance of common stock and pre-funded warrants in private placement
239,972
0
-
0
Payments of common stock and pre-funded warrants issuance costs in private placement
13,644
0
0
0
Proceeds from issuance of common stock in at-the-market public offering, net of sales commissions
60,801
5,117
1,419
246
Proceeds from exercises of common stock options
78
0
0
6
Employee stock purchase plan purchases
291
229
0
196
Payments of principal portion of finance lease obligations
0
203
243
277
Net cash provided by financing activities
287,498
5,143
1,176
188,127
Net increase in cash, cash equivalents, and restricted cash
98,850
-1,398
-77,569
58,670
Cash, cash equivalents, and restricted cash at beginning of period
61,890
63,288
82,187
-
Cash, cash equivalents, and restricted cash at end of period
160,740
61,890
63,288
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from issuance of
common stock and...
$239,972K
Proceeds from issuance of
common stock in...
$60,801K
(24615.85%↑ Y/Y)
Employee stock purchase
plan purchases
$291K
(48.47%↑ Y/Y)
Proceeds from exercises
of common stock...
$78K
(1200.00%↑ Y/Y)
Net cash provided by
financing activities
$287,498K
(52.82%↑ Y/Y)
Canceled cashflow
$13,644K
Net increase in
cash, cash...
$98,850K
(68.48%↑ Y/Y)
Canceled cashflow
$188,648K
Payments of common stock
and pre-funded...
$13,644K
Equity-based compensation
expense
$10,768K
(66.02%↑ Y/Y)
Change in fair value of
derivative liabilities
-$2,500K
(1.96%↑ Y/Y)
Non-cash lease expense
$1,257K
(8.18%↑ Y/Y)
Accounts payable
$1,139K
(143.90%↑ Y/Y)
Depreciation and
amortization expense
$786K
(-0.88%↓ Y/Y)
Other
-$25K
(54.55%↑ Y/Y)
Proceeds from maturities
of...
-$146,880K
(-112.87%↓ Y/Y)
Net cash used in
operating activities
-$99,817K
(-44.12%↓ Y/Y)
Net cash used in
investing activities
-$88,831K
(-47.57%↓ Y/Y)
Canceled cashflow
$16,475K
Canceled cashflow
$146,880K
Net loss
-$111,536K
(-41.61%↓ Y/Y)
Purchases of
available-for-sale securities
$235,396K
(82.79%↑ Y/Y)
Amortization of discount on
available-for-sale securities
$1,984K
(148.00%↑ Y/Y)
Accrued expenses and
other liabilities
-$1,442K
(-185.07%↓ Y/Y)
Change in operating
lease liability
-$1,006K
(-18.63%↓ Y/Y)
Prepaid expenses and
other assets
$324K
(-84.27%↓ Y/Y)
Purchases of property and
equipment
$315K
(-37.38%↓ Y/Y)
Buy us a coffee
Solid Biosciences Inc. (SLDB)
Solid Biosciences Inc. (SLDB)